Lancet Oncology Review - Combining Hyperthermia With the Major Cancer Therapies
SALT LAKE CITY, Sept. 5, 2002 /PRNewswire-FirstCall/ --
Lancet Oncology has published an invited review of recent breakthrough developments in hyperthermia therapy in which BSD Medical Corp.
(OTC Bulletin Board: BSDM) products are extensively referenced (see "Hyperthermia in combined treatment of cancer" -- Lancet Oncology, 2002, Vol. 3, pp. 487-497). The peer-reviewed article, with eight authors and 70 references, underscores very positive clinical results for all five of the cancer therapies served by BSD hyperthermia systems (i.e., local, interstitial, endocavitary, regional and party-body hyperthermia).
BSD Medical's hyperthermia applicators, the BSD-2000/3D and the BSD-2000/3D/MR are shown in the illustrations. The London based Lancet publications are widely followed, the largest distribution among world subscribers being to the United States.
Hyperthermia cancer therapy has drawn world attention following a recent technological breakthrough that allows tumor treatment to be monitored with magnetic resonance imaging (MRI) during hyperthermia treatments. BSD Medical and SIEMENS Medical Systems collaborated to develop a hybrid hyperthermia/MRI system, the BSD 2000/3D/MR.
The "online" images that this system produces are used to monitor changes in temperature and blood circulation during treatment, making hyperthermia therapy much more accurate than ever before.
The gist of the Lancet review is that although prior equipment demonstrated that adding hyperthermia therapy can impressively improve the success of results from radiation and chemotherapy, new technology has the potential to take the success rate significantly higher.
Hyperthermia increases blood flow in tumors to allow more chemotherapy drug to be carried into tumors, and it oxygenates tumors so that radiation therapy can form the oxygen radicals required to kill cancer cells.
The review presented the findings of 18 phase III clinical trials combining hyperthermia with other treatments involving cancers of the breast, head and neck, melanoma, glioblastoma, rectum, esophagus, stomach, cervix and bladder.
"It's about saving more of the 550,000 people in the United States and many others in the world who die each year from cancer," according to Hyrum A. Mead, President of BSD Medical Corporation. "It isn't good enough that we continue to lose half of cancer victims.
The standard therapies, radiation and chemotherapy, must become more effective. Every incremental improvement in the survival rate can save many thousands. That is the mission of our business."
Principal author of the review is Professor Peter Wust, MD, PhD of Charite Medical School of Humboldt University in Berlin, Germany. For further information visit www.bsdmc.com .
Breast Cancer News is brought to you by the The MID HUDSON OPTIONS PROJECT, INC a grassroots Breast Cancer Health Advocacy, Support and Activist Group.
Ann's NOTE: Although this article was written as a promo for a particular company, the information is useful.
|Remember we are NOT Doctors and have NO medical training.|
This site is like an Encyclopedia - there are many pages, many links on many topics.
Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.